Vigo is pleased to have supported Elevara Medicines on its successful launch, including a $70m Series A financing to advance its lead programme into Phase 2 clinical trials in rheumatoid arthritis and to expand its pipeline into other chronic inflammatory and women’s health conditions.

Author